EuroPCR 2021 | Evolut Low Risk: Two-Year Results of The Self-Expanding Valve in Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) with the Evolut self-expanding valve was non-inferior to surgery in patients with low surgical risk. After two years, the primary endpoint of death or disabling stroke was similar between both strategies.

Evolut Low Risk

This presentation at EuroPCR 2021 reinforces the results presented during the American College of Cardiology (ACC) 2019 Congress and published in the New England Journal of Medicine (NEJM). At the time, a Bayesian analysis had been performed to estimate two-year outcomes when 850 of the 1414 patients included had reached only one year of follow-up.

All patients have now reached two years of follow-up and the plan is to extend the follow-up to 10 years.

After two years, the primary endpoint (all-cause mortality and disabling stroke) was observed in 4.3% of those who underwent TAVR vs. 6.3% of those who underwent surgery. This difference was not statistically significant, which confirms non-inferiority—albeit non-superiority.

When considering the endpoints separately, we see that all-cause mortality was 3.5% vs. 4.4% (p = 0.366), and disabling stroke was 1.5% vs. 2.7% (= 0.11).

Differences were found in the need of permanent pacemaker, regarding which surgery was better (21.1% for TAVR vs. 7.9% for surgery).


Read also: EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development.


Over these two years, better implantation techniques were developed using Evolut, such as overlapping the valves, which could reduce the difference. Something similar happens with paravalvular leak, regarding which surgery was superior (mild leaks: 26.6% for TAVR vs. only 2.6% for surgery; p < 0.001). However, the same technique refinement that improved the need for pacemaker also had an impact on leaks.

In terms of valve hemodynamics, Evolut had lower gradients and larger valvular areas than surgical ones.

Original Title: Complete 2-year follow-up from the Evolut low risk trial.

Reference: Presentado por Forrest J. en el EuroPCR 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...